News

Todos Medical to Host Business Update Conference Call on December 2nd at 4:30 PM EST

SmallCaps Daily December 1, 2021

296 3 minutes read

[ad_1]

New York, NY, and Tel Aviv, ISRAEL – (NewMediaWire) – December 01, 2021 – Todos Medical, Ltd. (“Todos Medical”) (OTCQB:
TOMDF), a comprehensive medical
diagnostics and related solutions company, today announced that the management
team of Todos Medical, including Mr. Gerald E. Commissiong, President and Chief
Executive Officer, will host a conference call on Thursday, December 2nd at
4:30 p.m. EST to discuss the Company’s business progress in 2021 and provide a
strategic outlook for the future.

The call information is as
follows:

· Date:
December 2, 2021

· Time:
4:30 p.m. Eastern Standard Time

· Direct
Dial-in number: (669) 900-6833

· Meeting
ID: 94945983568

· Passcode:
167897

This call is being webcast and
can be accessed at https://audience.mysequire.com/webinar-view?webinar_id=6b97aec0-7ccb-4754-9a33-5c26d34d9597.

The call will also be available
for replay by accessing https://audience.mysequire.com/webinar-view?webinar_id=6b97aec0-7ccb-4754-9a33-5c26d34d9597.

For more information, please
visit www.todosmedical.com. For more information on the Company’s CLIA/CAP
certified lab Provista Diagnostics, Inc. please visit www.provistadx.com.

About Todos Medical Ltd.

Founded in Rehovot, Israel with
offices in New York City, Todos Medical Ltd. (OTCQB: TOMDF) engineers
life-saving diagnostic solutions for the early detection of a variety of
cancers. In 2021, Todos completed the acquisition of U.S.-based medical
diagnostics company Provista Diagnostics, Inc. to gain rights to its
Alpharetta, Georgia-based CLIA/CAP certified lab currently performing PCR COVID
testing and Provista’s proprietary commercial-stage Videssa® breast cancer
blood test. The Company’s state-of-the-art and patented Todos Biochemical
Infrared Analyses (TBIA) is a proprietary cancer-screening technology using
peripheral blood analysis that deploys deep examination into cancer’s influence
on the immune system, looking for biochemical changes in blood mononuclear
cells and plasma. Todos’ two internally-developed cancer-screening tests, TMB-1
and TMB-2, have received a CE mark in Europe. Todos is focused on the
commercialization of Videssa and will bring the TBIA tests to market
thereafter.

Todos has entered into a joint
venture with NLC Pharma targeting diagnostic and testing solutions to address
the COVID-19 pandemic. The Joint-Venture is pursuing the development of
diagnostic tests targeting the 3CL protease, as well as 3CL protease inhibitors
that target a fundamental reproductive mechanism of coronaviruses. The
Company’s proprietary therapeutic candidate Tollovir™ is currently in a Phase 2
clinical trial to treat hospitalized COVID-19 patients in Israel, and is
preparing to initiate Phase 2/3 clinical trials for both hospitalized and
non-hospitalized patients in Israel.

Todos is also developing blood
tests for the early detection of neurodegenerative disorders, such as
Alzheimer’s disease. The Lymphocyte Proliferation Test (LymPro Test™) is a
diagnostic blood test that determines the ability of peripheral blood
lymphocytes (PBLs) and monocytes to withstand an exogenous mitogenic
stimulation that induces them to enter the cell cycle. It is believed that
certain diseases, most notably Alzheimer’s disease, are the result of
compromised cellular machinery that leads to aberrant cell cycle re-entry by
neurons, which then leads to apoptosis. LymPro is unique in the use of
peripheral blood lymphocytes as a surrogate for neuronal cell function,
suggesting a common relationship between PBLs and neurons in the brain.

Todos is also distributing
certain (COVID-19) testing materials and supplies to CLIA-certified labs in the
United States. The products cover multiple suppliers of PCR testing kits,
extraction kits, automation materials and supplies, as well as COVID-19
antibody and antigen testing kits.

For more information, please
visit https://www.todosmedical.com/.

Forward-looking Statements

Certain statements contained in
this press release may constitute forward-looking statements. For example,
forward-looking statements are used when discussing our expected clinical
development programs and clinical trials. These forward-looking statements are
based only on current expectations of management, and are subject to
significant risks and uncertainties that could cause actual results to differ
materially from those described in the forward-looking statements, including
the risks and uncertainties related to the progress, timing, cost, and results
of clinical trials and product development programs; difficulties or delays in
obtaining regulatory approval or patent protection for product candidates;
competition from other biotechnology companies; and our ability to obtain
additional funding required to conduct our research, development and
commercialization activities. In addition, the following factors, among others,
could cause actual results to differ materially from those described in the
forward-looking statements: changes in technology and market requirements;
delays or obstacles in launching our clinical trials; changes in legislation;
inability to timely develop and introduce new technologies, products and
applications; lack of validation of our technology as we progress further and
lack of acceptance of our methods by the scientific community; inability to
retain or attract key employees whose knowledge is essential to the development
of our products; unforeseen scientific difficulties that may develop with our
process; greater cost of final product than anticipated; loss of market share
and pressure on pricing resulting from competition; and laboratory results that
do not translate to equally good results in real settings, all of which could
cause the actual results or performance to differ materially from those
contemplated in such forward-looking statements. Except as otherwise required
by law, Todos Medical does not undertake any obligation to publicly release any
revisions to these forward-looking statements to reflect events or
circumstances after the date hereof or to reflect the occurrence of
unanticipated events. For a more detailed description of the risks and
uncertainties affecting Todos Medical, please refer to its reports filed from
time to time with the U.S. Securities and Exchange Commission.